Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.24 AUD | +2.97% | +2.21% | +51.19% |
Sales 2024 * | 741M 490M | Sales 2025 * | 937M 619M | Capitalization | 5.04B 3.33B |
---|---|---|---|---|---|
Net income 2024 * | 48M 31.72M | Net income 2025 * | 103M 68.06M | EV / Sales 2024 * | 6.62 x |
Net cash position 2024 * | 128M 84.44M | Net cash position 2025 * | 195M 129M | EV / Sales 2025 * | 5.17 x |
P/E ratio 2024 * |
101
x | P/E ratio 2025 * |
48.4
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +2.97% | ||
1 week | +2.21% | ||
Current month | +1.26% | ||
1 month | +27.00% | ||
3 months | +26.79% | ||
6 months | +64.94% | ||
Current year | +51.19% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 16 M€ | -4.51% | ||
0.04% | 773 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 15.24 | +2.97% | 1,179,463 |
24-05-02 | 14.8 | +0.89% | 1,164,035 |
24-05-01 | 14.67 | -2.52% | 1,349,905 |
24-04-30 | 15.05 | -2.97% | 1,355,980 |
24-04-29 | 15.51 | +4.02% | 1,278,885 |
Delayed Quote Australian S.E., May 03, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.19% | 3.33B | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- TLX Stock